Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$88 Mln
P/E Ratio
--
P/B Ratio
0.69
Industry P/E
--
Debt to Equity
0.32
ROE
-0.5 %
ROCE
-39.38 %
Div. Yield
0 %
Book Value
1.85
EPS
-1.07
CFO
$-784.09 Mln
EBITDA
$-1,029.22 Mln
Net Profit
$-897.59 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
MacroGenics (MGNX)
| -47.38 | -14.29 | -44.48 | -88.90 | -39.73 | -24.76 | -25.78 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
MacroGenics (MGNX)
| -65.92 | 43.37 | -58.19 | -29.79 | 110.11 | -14.33 | -33.01 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific... DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850 Read more
President, CEO & Director
Dr. Scott Koenig M.D., Ph.D.
President, CEO & Director
Dr. Scott Koenig M.D., Ph.D.
Headquarters
Rockville, MD
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of MacroGenics Inc (MGNX) stood at $ 262 Mln as on 31-Dec-24
The share price of MacroGenics Inc (MGNX) is $1.71 (NASDAQ) as of 23-Apr-2025 16:19 EDT. MacroGenics Inc (MGNX) has given a return of -39.73% in the last 3 years.
MacroGenics Inc (MGNX) has a market capitalisation of $ 88 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of MacroGenics Inc (MGNX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the MacroGenics Inc (MGNX) and enter the required number of quantities and click on buy to purchase the shares of MacroGenics Inc (MGNX).
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland. Address: 9704 Medical Center Drive, Rockville, MD, United States, 20850
The CEO & director of Dr. Scott Koenig M.D., Ph.D.. is MacroGenics Inc (MGNX), and CFO & Sr. VP is Dr. Scott Koenig M.D., Ph.D..
There is no promoter pledging in MacroGenics Inc (MGNX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| MacroGenics Inc. (MGNX) | Ratios |
|---|---|
|
Return on equity(%)
|
-49.85
|
|
Operating margin(%)
|
-43.28
|
|
Net Margin(%)
|
-44.66
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of MacroGenics Inc (MGNX) was $0 Mln.
$0.19
(
